JERUSALEM--(BUSINESS WIRE)--Oramed Pharmaceuticals, Inc. (OTCBB:ORMP), a leading developer of the oral insulin gel capsule, is pleased to announce the closing of a financing of over $2 million into the Company by a number of leading private investors with strong connections to the pharmaceutical industry. The placement was at $0.50 per share with a warrant priced at $0.75.
